Loading...
  • PBSC
  • Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. (clinicaltrials.gov)
  • Followed by Stem Cell Rescue
  • Consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses (C) and 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks (R), the order of which depends on patient age, in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • clinical
  • As a step forward to improving the efficiency and reducing the cost of culture conditions, lead author Dr. Ann Dahlberg in the Clinical Research Division reports in the journal Leukemia that alteration of two important signaling pathways expands stem and progenitor cells in cultured cord blood. (fredhutch.org)
  • Breakthrough studies led by Drs. Colleen Delaney and Irv Bernstein in the Clinical Research Division demonstrated that cord blood stem and progenitor cells could be expanded by treating cells with specific cytokines and inducing Notch signaling (Delaney et al . (fredhutch.org)
  • This method is currently in human clinical trials to improve cord blood stem cell transplant. (fredhutch.org)
  • The widespread availability of clinical transplant results may help researchers recognize the limits of MHC mismatching," says Effie Wang Petersdorf, M.D., professor at the University of Washington School of Medicine and Member of the Fred Hutchinson Cancer Research Center, who leads the team of researchers and clinicians contributing transplant data to the project. (innovations-report.com)
  • Additional rounds of bone marrow harvest and clinical applications to mobilize blood stem cells are often required. (redorbit.com)
  • Lam is a clinical hematologist-bioengineer at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, associate professor of pediatrics at Emory University School of Medicine and a faculty member in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory. (eurekalert.org)
  • She enrolled in a clinical trial, and received a half match transplant from her son. (kucancercenter.org)
  • While being initially used for treatment of connective tissue disorders due to their potential to differentiate into bone, cartilage, and fat cells, the discovery that MSCs can secrete cytokines and growth factors with antiapoptotic, proangiogenic, neuroprotective, and immune-modulatory properties has sparked broad clinical interest [ 2 - 4 ]. (hindawi.com)
  • The trial was conducted at the NIH Clinical Center in Bethesda, Md., by NIH researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases. (highlighthealth.com)
  • PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant works in treating patients with hematologic cancer or other disease. (clinicaltrials.gov)
  • This protocol allows for ongoing data collection to assess the long-term clinical and psychosocial outcomes of pediatric patients who have received a hematopoietic stem cell transplant at St. Jude Children's Research Hospital. (clinicaltrials.gov)
  • acute
  • Systemically infused mesenchymal stem cells (MSCs) are emerging therapeutics for treating stroke, acute injuries, and inflammatory diseases of the central nervous system (CNS), as well as brain tumors due to their regenerative capacity and ability to secrete trophic, immune modulatory, or other engineered therapeutic factors. (hindawi.com)
  • This phase II trial studies the side effects and how well giving busulfan and etoposide followed by peripheral blood stem cell transplant (PBSCT) and low-dose aldesleukin works in treating patients with acute myeloid leukemia (AML). (clinicaltrials.gov)